ID   HepDE19
AC   CVCL_M178
SY   DE19
DR   Wikidata; Q54882838
RX   PubMed=17804499;
RX   PubMed=17875990;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Derived from sampling site: Liver.
DI   NCIt; C3728; Hepatoblastoma
DI   ORDO; Orphanet_449; Hepatoblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0027 ! Hep-G2
SX   Male
AG   15Y
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 20-05-21; Version: 14
RX   PubMed=17804499; DOI=10.1128/JVI.01123-07;
RA   Guo H.-T., Jiang D., Zhou T.-L., Cuconati A., Block T.M., Guo J.-T.;
RT   "Characterization of the intracellular deproteinized relaxed circular
RT   DNA of hepatitis B virus: an intermediate of covalently closed
RT   circular DNA formation.";
RL   J. Virol. 81:12472-12484(2007).
RX   PubMed=17875990; DOI=10.1128/AAC.00541-07;
RA   Dougherty A.M., Guo H.-T., Westby G., Liu Y.-J., Simsek E., Guo J.-T.,
RA   Mehta A., Norton P., Gu B.-H., Block T.M., Cuconati A.;
RT   "A substituted tetrahydro-tetrazolo-pyrimidine is a specific and novel
RT   inhibitor of hepatitis B virus surface antigen secretion.";
RL   Antimicrob. Agents Chemother. 51:4427-4437(2007).